Pancryos strikes deal with Brigham and Women’s Hospital on type 1 diabetes drug

The Copenhagen-based firm has entered a global license agreement with Brigham and Women’s Hospital regarding an encapsulation device for the delivery of a stem-cell derived treatment for type 1 diabetes.
Jacqueline Ameri, CEO of Pancryos | Photo: Bioinnovation Institute / PR
Jacqueline Ameri, CEO of Pancryos | Photo: Bioinnovation Institute / PR
by christopher due karlsson, translated by daniel pedersen

Pancryos, which is based out of Copenhagen, Denmark, is working on a stem-cell based treatment for type 1 diabetes dubbed Paninsula, and has now signed an exclusive license deal with the US-based Brigham and Women’s Hospital (BWH), the firm reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading